Investigating Max as a tumor suppressor gene in small cell lung cancer and other neuroendocrine tumors
Investigating Max as a tumor suppressor gene in small cell lung cancer and other neuroendocrine tumors
批准号:
10400844
负责人:
Robert Neil Eisenman
金额:
$54.4万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-05-01 至 2025-04-30
关键词:
AffectApoptosisAutomobile DrivingBindingBinding SitesBiologicalCandidate Disease GeneCarbonCell LineCell ProliferationCell modelCellsChIP-seqChromatinClustered Regularly Interspaced Short Palindromic RepeatsCommon CarcinomaComplementComplexDataDeletion MutationDimerizationEpigenetic ProcessEquilibriumEtiologyFamilyFamily memberGene ExpressionGenesGeneticGenetic TranscriptionGenome StabilityGenomic DNAGenomic InstabilityGenomicsGrowthHeterodimerizationHumanLaboratoriesLeadLesionMYC Family ProteinMYCL1 geneMYCN geneMalignant NeoplasmsMalignant neoplasm of thyroidMetabolic PathwayMetabolismModelingMolecularMolecular AnalysisMolecular GeneticsMusMutationNeoplasmsNeuroendocrine TumorsNeurosecretory SystemsOncogenicPathway interactionsPharmacologyPhenotypePheochromocytomaPropertyProteinsPublic HealthReportingResearchRoleSiteSystemTP53 geneThyroid GlandTimeTumor SuppressionTumor Suppressor GenesTumor Suppressor ProteinsTumor stageWorkbasebiological systemscancer therapydimerin vivoin vivo Modelloss of functionlung small cell carcinomamedullary thyroid carcinomamembermortalitymouse modelmutantneoplasticneuroendocrine cancernovelnovel strategiesoverexpressiontherapeutic targettranscription factortranscriptome sequencingtumortumorigenesistumorigenicwhole genome
中文摘要
摘要
转录调节因子MYC家族的异常表达是广泛的
人类癌症的谱系,包括小细胞肺癌(SCLC),一种高度侵袭性的神经内分泌-
一种肿瘤,是美国癌症死亡的主要原因之一。特异性MYC家族蛋白
与MAX异源二聚,以结合基因组DNA并刺激广泛的转录。令人惊讶的是,
最近的报告显示,MAX通过删除和截断突变在一个重要的子集
小细胞肺癌和其他神经内分泌癌。自相矛盾的是,麦克斯可能是一种肿瘤抑制因子,但实际上
对小细胞肺癌的MYC致癌性至关重要,这对于我们理解这些疾病的病因具有重要的意义。
肿瘤,但尚未进行系统研究。这项建议是基于我们两人的研究结果
实验室发现(I)癌前小细胞肺癌(Prescs)的全基因组CRISPR失活筛查
MAX靶向的sgRNAs是高度促进生长的;和(Ii)MAX的缺失显著加速了SCLC
在一个原生小鼠模型中。这些结果首次为生物系统提供了高度相关的
阐明MAX的肿瘤抑制功能。
在目标1中,我们将表征MAX缺失的小细胞肺癌的生物学特性,包括增殖、凋亡
和基因组的稳定性。此外,我们将使用ChIP-Seq和RNA-Seq来确定
小细胞肺癌中MYC/MYCL和MAX结合及靶基因表达我们将在功能上
询问通过综合基因组分析确定的关键MAX目标基因的重要性。目标为
研究将包括已确定的一种碳代谢的MAX依赖调节因子。AIM 2是基于
关于MAX缺失不仅改变MYC活动而且扰乱更广泛的MYC-MAX的假设
激活因子和抑制因子的转录网络。我们将确定MYC/MYCL是否有MAX独立
在我们的小细胞肺癌模型和人小细胞肺癌细胞系中的致癌功能,并检查网络成员
对抗或与MYC合作(如MXD/MNT、MLX和Mondoa),影响SCLC
进步。在目标3中,我们建议确定核心MAX调节的基因和共同的途径
MAX对神经内分泌肿瘤的抑制作用这将需要我们新的分子和基因特征
最大缺失(Rb/P53)所致甲状腺髓样癌和嗜铬细胞瘤模型
不足的背景)以及与Max-Null SCLC共享的通路的识别。这项研究将扩大
我们的研究范围广泛,以揭示MAX是如何抑制神经内分泌癌的。我们预计这些
研究将加深我们对MYC网络在驱动和抑制中的复杂作用的理解
并确定可能成为治疗靶点的新的肿瘤形成途径。
英文摘要
SUMMARY
Dysregulated expression of the MYC family of transcriptional regulators is a common denominator in a wide
spectrum of human cancers, including small cell lung carcinoma (SCLC), a highly aggressive neuroendocrine-
type tumor that is among the leading causes of US cancer mortality. MYC family proteins specifically
heterodimerize with MAX in order to bind genomic DNA and stimulate widespread transcription. Surprisingly,
recent reports show that MAX is inactivated through deletions and truncating mutations in a significant subset of
SCLC and other neuroendocrine cancers. The paradox that MAX may act as a tumor suppressor, but yet be
crucial for MYC oncogenicity in SCLC, has important implications for our understanding of the etiology of these
tumors but has not been systematically investigated. This proposal is based on the findings from our two
laboratories that (i) a whole-genome CRISPR inactivation screen in pre-neoplastic SCLC (preSCs) revealed
MAX-targeting sgRNAs to be highly growth promoting; and (ii) deletion of MAX dramatically accelerates SCLC
in an autochthonous mouse model. These results provide, for the first time, highly relevant biological systems to
elucidate MAX's tumor suppressor function.
In Aim 1 we will characterize the biological properties of MAX-deleted SCLC including proliferation, apoptosis
and genomic stability. Moreover, we will use ChIP-Seq and RNA-Seq to determine the genomic landscape of
MYC/MYCL and MAX binding and target gene expression in SCLC and MAX-deleted SCLC. We will functionally
interrogate the importance of key MAX target genes identified through integrative genomic analyses. Targets to
be studied will include MAX-dependent regulators of one carbon metabolism already identified. Aim 2 is based
on the hypothesis that MAX deletion not only alters MYC activity but disrupts the broader MYC- MAX
transcriptional network of activators and repressors. We will determine if MYC/MYCL have MAX independent
oncogenic functions in our SCLC models and in human SCLC cell lines, and examine whether network members
that antagonize or cooperate with MYC (such as MXD/MNT, MLX, and MondoA), act to influence SCLC
progression. In Aim 3 we propose to determine core MAX-regulated genes and pathways common to
neuroendocrine tumor suppression by MAX. This will entail molecular and genetic characterization of our new
models of thyroid medullary carcinomas and pheochromocytomas resulting from MAX loss (in an Rb/p53
deficient background) and identification of pathways shared with MAX-null SCLC. This research will extend the
breadth of our studies to uncover how MAX suppresses neuroendocrine cancers. We anticipate that these
studies will deepen our understanding of the complex role of the MYC network in both driving and suppressing
neoplasia and identify novel tumorigenic pathways that may have the potential to serve as therapeutic targets.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Investigating Max as a tumor suppressor gene in small cell lung cancer and other neuroendocrine tumors
-
批准号:10662195
-
项目类别:
-
资助金额:$54.4万
-
财政年份:2020
-
负责人:Robert Neil Eisenman
-
依托单位:
Investigating Max as a tumor suppressor gene in small cell lung cancer and other neuroendocrine tumors
-
批准号:10601282
-
项目类别:
-
资助金额:$14.73万
-
财政年份:2020
-
负责人:Robert Neil Eisenman
-
依托单位:
The MYC Transcription Factor Network and the Path to Cancer
-
批准号:10477962
-
项目类别:
-
资助金额:$103.49万
-
财政年份:2018
-
负责人:Robert Neil Eisenman
-
依托单位:
The MYC Transcription Factor Network and the Path to Cancer
-
批准号:10601462
-
项目类别:
-
资助金额:$47.99万
-
财政年份:2018
-
负责人:Robert Neil Eisenman
-
依托单位:
The MYC Transcription Factor Network and the Path to Cancer
-
批准号:9762884
-
项目类别:
-
资助金额:$102.43万
-
财政年份:2018
-
负责人:Robert Neil Eisenman
-
依托单位:
The MYC Transcription Factor Network and the Path to Cancer
-
批准号:10684160
-
项目类别:
-
资助金额:$103.49万
-
财政年份:2018
-
负责人:Robert Neil Eisenman
-
依托单位:
The MYC Transcription Factor Network and the Path to Cancer
-
批准号:10228620
-
项目类别:
-
资助金额:$57.61万
-
财政年份:2018
-
负责人:Robert Neil Eisenman
-
依托单位:
Control of Neural Stem Cell Identity by Tafs and Trf2
-
批准号:9223743
-
项目类别:
-
资助金额:$22.0万
-
财政年份:2016
-
负责人:Robert Neil Eisenman
-
依托单位:
Directed Evolution of Peptide Inhibitors of Myc-Max Dimerization (PQ18)
-
批准号:8534068
-
项目类别:
-
资助金额:$17.99万
-
财政年份:2012
-
负责人:Robert Neil Eisenman
-
依托单位:
Directed Evolution of Peptide Inhibitors of Myc-Max Dimerization (PQ18)
-
批准号:8384773
-
项目类别:
-
资助金额:$22.97万
-
财政年份:2012
-
负责人:Robert Neil Eisenman
-
依托单位:
Transcription Factors in Stem Cell Self-Renewal and Differentation
-
批准号:7226080
-
项目类别:
-
资助金额:$47.77万
-
财政年份:2006
-
负责人:Robert Neil Eisenman
-
依托单位:
Growth regulatory targets of the Tuberous Sclerosis Complex
-
批准号:7848110
-
项目类别:
-
资助金额:$37.42万
-
财政年份:2006
-
负责人:Robert Neil Eisenman
-
依托单位:
Growth regulatory targets of the Tuberous Sclerosis Complex
-
批准号:7627187
-
项目类别:
-
资助金额:$37.8万
-
财政年份:2006
-
负责人:Robert Neil Eisenman
-
依托单位:
MYC TRANSCRIPTION FACTOR NETWORK IN STEM CELL BIOLOGY
-
批准号:6652840
-
项目类别:
-
资助金额:$20.94万
-
财政年份:2002
-
负责人:Robert Neil Eisenman
-
依托单位:
MYC TRANSCRIPTION FACTOR NETWORK IN STEM CELL BIOLOGY
-
批准号:6494848
-
项目类别:
-
资助金额:$20.94万
-
财政年份:2001
-
负责人:Robert Neil Eisenman
-
依托单位:
MYC TRANSCRIPTION FACTOR NETWORK IN STEM CELL BIOLOGY
-
批准号:6358970
-
项目类别:
-
资助金额:$20.94万
-
财政年份:2000
-
负责人:Robert Neil Eisenman
-
依托单位:
MYC TRANSCRIPTION FACTOR NETWORK IN STEM CELL BIOLOGY
-
批准号:6202421
-
项目类别:
-
资助金额:$20.18万
-
财政年份:1999
-
负责人:Robert Neil Eisenman
-
依托单位:
MYC TRANSCRIPTION FACTOR NETWORK IN STEM CELL BIOLOGY
-
批准号:6110533
-
项目类别:
-
资助金额:$20.18万
-
财政年份:1998
-
负责人:Robert Neil Eisenman
-
依托单位:
MYC TRANSCRIPTION FACTOR NETWORK IN STEM CELL BIOLOGY
-
批准号:6242527
-
项目类别:
-
资助金额:$20.27万
-
财政年份:1997
-
负责人:Robert Neil Eisenman
-
依托单位:
FASEB RESEARCH CONFERENCE: TRANSCRIPTION REGULATION
-
批准号:2205003
-
项目类别:
-
资助金额:$0.51万
-
财政年份:1994
-
负责人:Robert Neil Eisenman
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位:
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
-
批准号:39500043
-
项目类别:青年科学基金项目
-
资助金额:9.0万元
-
批准年份:1995
-
负责人:梁克
-
依托单位: